Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Tyra Biosciences, Inc. (TYRA : NSDQ)
 
 • Company Description   
Tyra Biosciences Inc. is a precision oncology company. It focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The company's lead product candidate includes TYRA-300. Tyra Biosciences Inc. is based in CARLSBAD, Calif.

Number of Employees: 60

 
 • Price / Volume Information   
Yesterday's Closing Price: $10.05 Daily Weekly Monthly
20 Day Moving Average: 407,523 shares
Shares Outstanding: 53.09 (millions)
Market Capitalization: $533.55 (millions)
Beta: 1.07
52 Week High: $29.60
52 Week Low: $6.42
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -2.05% -6.08%
12 Week 26.89% 11.19%
Year To Date -27.70% -31.71%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2656 STATE STREET
-
CARLSBAD,CA 92008
USA
ph: 619-728-4760
fax: -
aconrad@tyra.bio http://www.tyra.bio
 
 • General Corporate Information   
Officers
Todd Harris - Chief Executive Officer and President
Alan Fuhrman - Chief Financial Officer
Adele M. Gulfo - Director
Gilla Kaplan - Director
Melissa McCracken - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 90240B106
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/06/25
Share - Related Items
Shares Outstanding: 53.09
Most Recent Split Date: (:1)
Beta: 1.07
Market Capitalization: $533.55 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.55 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.12 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/06/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.65
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -34.29%
vs. Previous Quarter: -9.30%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -26.90
12/31/24 - -22.98
ROA
06/30/25 - -
03/31/25 - -25.54
12/31/24 - -21.94
Current Ratio
06/30/25 - -
03/31/25 - 22.78
12/31/24 - 23.81
Quick Ratio
06/30/25 - -
03/31/25 - 22.78
12/31/24 - 23.81
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 6.09
12/31/24 - 6.78
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©